These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 19233048)

  • 1. The economics of treatment in early rheumatoid arthritis.
    Bansback N; Marra CA; Finckh A; Anis A
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen JH
    Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic consequences of established rheumatoid arthritis and its treatment.
    Kavanaugh A
    Best Pract Res Clin Rheumatol; 2007 Oct; 21(5):929-42. PubMed ID: 17870036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis?
    March L; Lapsley H
    Best Pract Res Clin Rheumatol; 2001 Mar; 15(1):171-85. PubMed ID: 11358421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
    van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC
    Arthritis Rheum; 2009 Mar; 61(3):291-9. PubMed ID: 19248130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Now that we know what's BeSt, what is good value for the money?
    Bansback N; Marra CA
    Arthritis Rheum; 2009 Mar; 61(3):289-90. PubMed ID: 19248126
    [No Abstract]   [Full Text] [Related]  

  • 7. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project).
    Hallert E; Husberg M; Skogh T
    Rheumatology (Oxford); 2006 Mar; 45(3):325-31. PubMed ID: 16287927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug management of early rheumatoid arthritis - 2008.
    Sokka T; Mäkinen H
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):93-102. PubMed ID: 19233049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of rheumatoid arthritis in Hungary.
    Péntek M; Kobelt G; Czirják L; Szekanecz Z; Poór G; Rojkovich B; Polgár A; Genti G; Kiss CG; Brodszky V; Májer I; Gulácsi L
    J Rheumatol; 2007 Jun; 34(6):1437. PubMed ID: 17552071
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rheumatoid arthritis: milestones in classification and treatment].
    Fiehn C
    Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early rheumatoid arthritis -- is there a window of opportunity?
    Cush JJ
    J Rheumatol Suppl; 2007 Nov; 80():1-7. PubMed ID: 17985417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
    Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health economics: implications for novel antirheumatic therapies.
    Kavanaugh A
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv65-9. PubMed ID: 16239392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacoeconomics of newer therapeutics for rheumatic diseases.
    Kavanaugh A
    Rheum Dis Clin North Am; 2006 Feb; 32(1):45-56, viii. PubMed ID: 16504820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmet needs in rheumatoid arthritis.
    Bykerk V
    J Rheumatol Suppl; 2009 Jun; 82():42-6. PubMed ID: 19509330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Back to the future: the managed care approach to rheumatoid arthritis.
    Sidorov J
    Manag Care Interface; 2007 Jul; 20(7):28-30. PubMed ID: 17849731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic consequences and potential benefits.
    Fautrel B; Verstappen SM; Boonen A
    Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):607-24. PubMed ID: 22137927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional disease-modifying antirheumatic drugs in early arthritis.
    Sokka T; Hannonen P; Möttönen T
    Rheum Dis Clin North Am; 2005 Nov; 31(4):729-44. PubMed ID: 16287594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes.
    Keystone EC
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):594-601. PubMed ID: 17075598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.